title: Use of hepatitis B core antibody-positive donor kidneys in hepatitis B surface antibody-positive and -negative recipients.
abstract: BACKGROUND
  The rate of hepatitis B virus transmission via organs from with isolated hepatitis B virus core antibody-positive (HBcAb+) donors in kidney transplant recipients seems very low.
  
  
  METHODS
  Over 4 years, we performed 36 transplants from Ig HBcAb+, hepatitis B surface antigen (HBsAg)-negative donors into recipients with a history of prior hepatitis B virus (HBV) infection or reported vaccination (28 patients) and in recipients who were not immunized and received a pretransplant prophylaxis with hepatitis B immunoglobulins. We examined the HBV-related outcomes in these 36 patients in comparison with 40 recipients of allografts from HBcAb- donors.
  
  
  RESULTS
  No patient receiving an allograft from an HBcAb+ donor developed clinical HBV infection or HBSAg positivity. The rate of seroconversion was 14.2% in immunized patients, 12.5% in nonimmunized patients, and 0% in the control group. The 17.8% of immunized patients developed elevated transaminases after transplant, in comparison with 25% and 10% in the nonimmunized patients and the control group, respectively. Graft and patient survival was 93% and 93% for immunized patients, 100% and 100% for nonimmunized patients, and 98% and 95% for the control group, respectively.
  
  
  CONCLUSIONS
  The use of anti-HBc antibody-positive kidneys was associated with no risk of transmission of HBV infection, without affecting graft and patient survival, and could be considered a safe way to expand the donor pool. Our preliminary results suggest that such kidneys could be safely transplanted even in not immunized patients who underwent a prophylaxis with hepatitis B immunoglobulins.
authors.affiliation: Organ Transplant Unit, Department of Surgery, Transplantation and Advanced Technologies, University Hospital of Catania, Catania, Italy. veroux@unict.it
authors.forename: M
authors.initials: M
authors.lastname: Veroux
authors.forename: C
authors.initials: C
authors.lastname: Puliatti
authors.forename: M
authors.initials: M
authors.lastname: Gagliano
authors.forename: D
authors.initials: D
authors.lastname: Cappello
authors.forename: M
authors.initials: M
authors.lastname: Macarone
authors.forename: D
authors.initials: D
authors.lastname: Vizcarra
authors.forename: M
authors.initials: M
authors.lastname: Spataro
authors.forename: M
authors.initials: M
authors.lastname: Di Mare
authors.forename: N
authors.initials: N
authors.lastname: Ginevra
authors.forename: P
authors.initials: P
authors.lastname: Veroux
mesh_terms: D006085:Graft Survival; D006509:Hepatitis B / Q000150:complications / Q000276:immunology*; D006510:Hepatitis B Antibodies / Q000097:blood*; D006512:Hepatitis B Core Antigens / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000401:mortality / Q000502:physiology*; D018579:Patient Selection; D012189:Retrospective Studies; D016019:Survival Analysis; D014019:Tissue Donors / Q000600:supply & distribution*
chemical_list: D006510:Hepatitis B Antibodies; D006512:Hepatitis B Core Antigens; D006514:Hepatitis B Surface Antigens